proxyvotesnow.com

Home › Companies › AMYLYX PHARMACEUTICALS INC. › 2023-2024

AMYLYX PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and AMYLYX PHARMACEUTICALS INC.’s Form 8-K, filed 2024-06-06 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 6Reported items
  • 165Asset managers
  • 1,142Fund votes
  • 2024-06-06Meeting date

Proxy season: 2023-2024 2025-2026

Explore AMYLYX PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by AMYLYX PHARMACEUTICALS INC.

These tallies are AMYLYX PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-06 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

AMYLYX PHARMACEUTICALS INC. — official shareholder meeting results, meeting held 2024-06-06
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Joshua Cohen 32,649,858---- 11,308,7458,341,537 Majority: yes
Elect Director: Daphne Quimi 32,463,982---- 11,494,6218,341,537 Majority: yes
Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm The stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending D 52,023,591162,947113,602 --0 Majority: yes
Proposal 3: Non-Binding, Advisory Vote on the Compensation of the Company's Named Executive Officers The stockholders of the Company approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers ("NEOs") 41,211,8312,708,17838,594 --8,341,537 Majority: yes

Source: AMYLYX PHARMACEUTICALS INC., Form 8-K, filed with the SEC on 2024-06-06 — read the filing on EDGAR.

How asset managers voted at the AMYLYX PHARMACEUTICALS INC. 2023-2024 meeting

Each item below shows how the 165 asset managers that disclosed a AMYLYX PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of AMYLYX PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on a non-binding, advisory basis, the compensation of our named executives officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 11 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 41,211,831AGAINST: 2,708,178

AMYLYX PHARMACEUTICALS INC.’s own tally for this item (“Proposal 3: Non-Binding, Advisory Vote on the Compensation of the Company's Named Executive Officers The stockholders of the Company approved, on a non-binding, advisory basis, the compensation of the Company's named exe”): 41,211,831 for, 2,708,178 against, per its Form 8-K filed 2024-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 67,975,587 outstanding shares: 61% for, 4% against (65% of the company cast a for/against vote).

The 162 asset managers below cast 92% of the shares they voted on this item FOR (34,444,602 for, 2,845,533 against).

FOR 92%8%
FOR: 34,444,602 (92.4%)AGAINST: 2,845,533 (7.6%)ABSTAIN: 2,729 (0.0%)
Largest asset managers voting on “To approve, on a non-binding, advisory basis, the compensation of our named executives officers.” at AMYLYX PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,462,2120 00For
BlackRock4,282,4270 00For
State Street2,978,388260 00For
FRANKLIN ADVISERS INC1,855,8860 00For
T. Rowe Price1,737,5200 00For
Charles Schwab1,735,7080 00For
Two Sigma1,442,4090 00For
Alyeska Investment Group, L.P.01,208,607 00Against
FARALLON CAPITAL MANAGEMENT LLC1,150,2200 00For
Rock Springs Capital Management LP1,011,4120 00For
Fidelity983,5530 00For
DE Shaw942,6600 00For
GEODE CAPITAL MANAGEMENT, LLC925,4750 00For
AQR892,3260 00For
Alpha Wave Global, LP840,8890 00For
Citadel725,5530 00For
American Century0684,916 00Against
JPMorgan645,4240 00For
FRANKLIN STRATEGIC SERIES633,5900 00For
STATE OF WISCONSIN INVESTMENT BOARD583,2220 00For
Graham Capital Management, L.P.550,5740 00For
Woodline Partners LP394,5600 00For
SILVERARC CAPITAL MANAGEMENT, LLC338,0450 00For
Hudson Bay Capital Management LP320,8550 00For
Federated Hermes315,0520 00For

Showing the 25 largest of 162 asset managers. See all 162 in the interactive database.

2. To vote, on a non-binding, advisory basis, on the preferred frequency of future advisory votes on the compensation of our named executives officers.

SECTION 14A SAY-ON-PAY VOTES

99.8% fund support · no official result

ONE YEAR 97%

The 99 asset managers below cast 99.8% of the shares they voted on this item FOR (26,532 for, 40 against).

FOR: 26,532 (0.1%)AGAINST: 40 (0.0%)ONE YEAR: 31,502,861 (97.2%)1-YEAR: 840,889 (2.6%)THREE YEARS: 53,981 (0.2%)
Largest asset managers voting on “To vote, on a non-binding, advisory basis, on the preferred frequency of future advisory votes on the compensa” at AMYLYX PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard00 00One Year
BlackRock00 00One Year
State Street00 00One Year
FRANKLIN ADVISERS INC00 00One Year
T. Rowe Price00 00One Year
Two Sigma00 00One Year
Alyeska Investment Group, L.P.00 00One Year
Rock Springs Capital Management LP00 00One Year
Fidelity00 00One Year
DE Shaw00 00One Year
GEODE CAPITAL MANAGEMENT, LLC00 00One Year
AQR00 00One Year
Alpha Wave Global, LP00 001-Year
Citadel00 00One Year
American Century00 00One Year
FRANKLIN STRATEGIC SERIES00 00One Year
STATE OF WISCONSIN INVESTMENT BOARD00 00One Year
Graham Capital Management, L.P.00 00One Year
Woodline Partners LP00 00One Year
SILVERARC CAPITAL MANAGEMENT, LLC00 00One Year
Hudson Bay Capital Management LP00 00One Year
First Trust00 00One Year
Aberdeen00 00One Year
MELLON INVESTMENTS Corp00 00One Year
Connor, Clark & Lunn Investment Management Ltd.00 00One Year

Showing the 25 largest of 99 asset managers. See all 99 in the interactive database.

3. To vote, on a non-binding, advisory basis, on the preferred frequency of future advisory votes on the compensation of our named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Combines 6 wordings of this item as funds reported it.

100% fund support · no official result

FOR 25%1 YEAR 73%

The 62 asset managers below cast 100% of the shares they voted on this item FOR (1,150,222 for, 0 against).

FOR: 1,150,222 (25.3%)ABSTAIN: 2,729 (0.1%)1 YEAR: 3,323,869 (73.2%)UNKNOWN: 39,097 (0.9%)ONE YEAR: 26,557 (0.6%)
Largest asset managers voting on “To vote, on a non-binding, advisory basis, on the preferred frequency of future advisory votes on the compensa” at AMYLYX PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Charles Schwab00 001 Year
FARALLON CAPITAL MANAGEMENT LLC1,150,2200 00For
JPMorgan00 001 Year
Federated Hermes00 001 Year
Northern Trust00 001 Year
AVIVA INVESTORS GLOBAL SERVICES LTD00 001 Year
PNC BANK, NATIONAL ASSOCIATION00 001 Year
MACKENZIE FINANCIAL CORP00 001 Year
John Hancock00 001 Year
Atom Investors LP00 00Unknown
Wellington00 001 Year
Lincoln Financial00 001 Year
Corient Private Wealth LLC00 001 Year
NEW YORK STATE COMMON RETIREMENT FUND00 001 Year
SEI00 001 Year
New York Life00 00One Year
ROCKEFELLER FINANCIAL LLC00 001 Year
GPS Funds I00 001 Year
Arizona State Retirement System00 001 Year
PRIMECAP MANAGEMENT CO/CA/00 001 Year
PRIMECAP Odyssey Funds00 001 Year
Bridge Builder Trust00 001 Year
BANK OF AMERICA NA00 001 Year
Man Group plc00 001 Year
TRUST FOR PROFESSIONAL MANAGERS00 001 Year

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.

4. Election of Directors: To elect the following persons to our board of directors, each to serve as a Class III director until the 2027 Annual Meeting of Stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: Daphne Quimi

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

74% Majority: yes · of votes cast

FOR 74%WITHHELD 26%
FOR: 32,463,982WITHHELD: 11,494,621

AMYLYX PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Daphne Quimi”): 32,463,982 for, 11,494,621 withheld, per its Form 8-K filed 2024-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 67,975,587 outstanding shares: 47.8% for, 17% withheld (65% of the company cast a for/withheld vote).

The 53 asset managers below cast 100% of the shares they voted on this item FOR (12,693,841 for, 0 against).

FOR 88%12%
FOR: 12,693,841 (87.8%)ABSTAIN: 1,758,722 (12.2%)
Largest asset managers voting on “Election of Directors: To elect the following persons to our board of directors, each to serve as a Class III ” at AMYLYX PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,213,6300 109,2000For
BlackRock2,318,9830 00For
State Street1,020,5630 1,5230For
Fidelity907,6000 53,8000For
Charles Schwab867,8540 00For
T. Rowe Price746,8000 00For
FRANKLIN STRATEGIC SERIES633,5900 00For
American Century00 337,2100Abstain
First Trust00 311,4830Abstain
JPMorgan293,1430 00For
Federated Hermes157,4120 00For
ALPS ETF Trust00 138,8790Abstain
TIAA130,6610 00For
BRIDGEWAY FUNDS INC00 130,0000Abstain
Aberdeen00 118,2470Abstain
Goldman Sachs00 97,3080Abstain
QUANTITATIVE MASTER SERIES LLC89,6390 00For
AQR00 72,8580Abstain
ProShares00 70,8230Abstain
Lincoln Financial70,0470 00For
Equitable17,6020 51,5420Abstain
Direxion Shares ETF Trust00 54,7560Abstain
Dimensional00 53,9810Abstain
John Hancock31,7760 19,5220For
Voya49,4640 00For

Showing the 25 largest of 53 asset managers. See all 53 in the interactive database.

5. Election of Directors: To elect the following persons to our board of directors, each to serve as a Class III director until the 2027 Annual Meeting of Stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: Joshua B. Cohen

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

74% Majority: yes · of votes cast

FOR 74%WITHHELD 26%
FOR: 32,649,858WITHHELD: 11,308,745

AMYLYX PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Joshua Cohen”): 32,649,858 for, 11,308,745 withheld, per its Form 8-K filed 2024-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 67,975,587 outstanding shares: 48.0% for, 17% withheld (65% of the company cast a for/withheld vote).

The 53 asset managers below cast 100% of the shares they voted on this item FOR (12,814,166 for, 0 against).

FOR 89%11%
FOR: 12,814,166 (88.7%)ABSTAIN: 1,638,397 (11.3%)
Largest asset managers voting on “Election of Directors: To elect the following persons to our board of directors, each to serve as a Class III ” at AMYLYX PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,213,6300 109,2000For
BlackRock2,318,9830 00For
State Street1,020,5630 1,5230For
Fidelity907,6000 53,8000For
Charles Schwab867,8540 00For
T. Rowe Price746,8000 00For
FRANKLIN STRATEGIC SERIES633,5900 00For
American Century00 337,2100Abstain
First Trust00 311,4830Abstain
JPMorgan293,1430 00For
Federated Hermes157,4120 00For
ALPS ETF Trust00 138,8790Abstain
TIAA130,6610 00For
BRIDGEWAY FUNDS INC00 130,0000Abstain
Aberdeen118,2470 00For
Goldman Sachs00 97,3080Abstain
QUANTITATIVE MASTER SERIES LLC89,6390 00For
AQR00 72,8580Abstain
ProShares00 70,8230Abstain
Lincoln Financial70,0470 00For
Equitable69,1440 00For
Direxion Shares ETF Trust00 54,7560Abstain
Dimensional00 53,9810Abstain
John Hancock31,7760 19,5220For
Voya00 49,4640Abstain

Showing the 25 largest of 53 asset managers. See all 53 in the interactive database.

6. To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.6% Majority: yes · of votes cast

FOR 99.6%
FOR: 52,023,591AGAINST: 162,947

AMYLYX PHARMACEUTICALS INC.’s own tally for this item (“Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm The stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Company's independent registered public acco”): 52,023,591 for, 162,947 against, per its Form 8-K filed 2024-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 67,975,587 outstanding shares: 77% for, 0.3% against (77% of the company cast a for/against vote).

The 53 asset managers below cast 100% of the shares they voted on this item FOR (14,452,563 for, 0 against).

FOR 100%
FOR: 14,452,563 (100.0%)
Largest asset managers voting on “To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for th” at AMYLYX PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard5,322,8300 00For
BlackRock2,318,9830 00For
State Street1,022,0860 00For
Fidelity961,4000 00For
Charles Schwab867,8540 00For
T. Rowe Price746,8000 00For
FRANKLIN STRATEGIC SERIES633,5900 00For
American Century337,2100 00For
First Trust311,4830 00For
JPMorgan293,1430 00For
Federated Hermes157,4120 00For
ALPS ETF Trust138,8790 00For
TIAA130,6610 00For
BRIDGEWAY FUNDS INC130,0000 00For
Aberdeen118,2470 00For
Goldman Sachs97,3080 00For
QUANTITATIVE MASTER SERIES LLC89,6390 00For
AQR72,8580 00For
ProShares70,8230 00For
Lincoln Financial70,0470 00For
Equitable69,1440 00For
Direxion Shares ETF Trust54,7560 00For
Dimensional53,9810 00For
John Hancock51,2980 00For
Voya49,4640 00For

Showing the 25 largest of 53 asset managers. See all 53 in the interactive database.

Largest AMYLYX PHARMACEUTICALS INC. shareholders voting in 2023-2024

Ranked by the number of AMYLYX PHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 67,975,587 shares outstanding at the time of that meeting.

Top AMYLYX PHARMACEUTICALS INC. shareholders by shares voted, 2023-2024
#Asset manager % of shares outstanding
1Vanguard 8.04%
2BlackRock 6.30%
3State Street 4.38%
4FRANKLIN ADVISERS INC 2.73%
5T. Rowe Price 2.56%
6Charles Schwab 2.55%
7Two Sigma 2.12%
8Alyeska Investment Group, L.P. 1.78%
9FARALLON CAPITAL MANAGEMENT LLC 1.69%
10Rock Springs Capital Management LP 1.49%

Reported AMYLYX PHARMACEUTICALS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

AMYLYX PHARMACEUTICALS INC. beneficial owners on record for the 2023-2024 proxy season
Holder % outstanding Disclosure
FMR (Fidelity) 16.74% 13F
BlackRock 10.50% 13F
Vanguard Group 7.76% 13F
Millennium Management 3.69% 13F
Citadel Advisors 3.33% 13F
State Street 3.03% 13F
Goldman Sachs 2.96% 13F
Morgan Stanley 2.87% 13F
Franklin Templeton 2.73% 13F
Two Sigma 2.11% 13F

Percentages above are of 67,975,587 shares outstanding, as reported by AMYLYX PHARMACEUTICALS INC. on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from AMYLYX PHARMACEUTICALS INC.’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At AMYLYX PHARMACEUTICALS INC.'s shareholder meeting held 2024-06-06, in the 2023-2024 proxy season, 165 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,142 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of our named executives officers. — FOR was 94% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: AMYLYX PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-06.

AMYLYX PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2025-2026.